<p>纽约，2025 年 12 月 26 日（GLOBE NEWSWIRE）-- Southpoint Capital Advisors LP（“Southpoint”）作为其担任投资经理的某些 Southpoint 基金的代表，宣布于 2025 年 12 月 24 日，根据证券法，处置了 Fennec Pharmaceuticals Inc.（“Fennec”）的 1,000,000 股普通股（“普通股”）的实益拥有权，约占已发行普通股的 2.93%（按完全稀释基础计算）。</p>
<p>普通股的出售价格为每股 7.50 美元。</p>
<p>Southpoint 目前对总计 270 万股普通股行使控制或指挥权，约占已发行普通股的 8%（按完全稀释基础计算）。</p>
<p>Southpoint 处置普通股是出于投资目的。根据市场和其他条件，Southpoint 可能会通过市场交易、私人协议、国库发行、行使认股权证或其他方式改变其对普通股的实益拥有权或控制或指挥权。</p>
<p>本新闻稿的发布是为了遵守适用的证券立法。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56UXdOaU0zTXpNM01UWXpJekl3T0RrNE5URT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56UXdOaU0zTXpNM01UWXpJekl3T0RrNE5URT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmQ5MWJkMjEtMDI0Zi00OGI2LWJlMmEtZDY4Y2I0MmZhMjE4LTExMDE0MjItMjAyNS0xMi0yNi1lbg==/tiny/Fennec-Pharmaceuticals-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmQ5MWJkMjEtMDI0Zi00OGI2LWJlMmEtZDY4Y2I0MmZhMjE4LTExMDE0MjItMjAyNS0xMi0yNi1lbg==/tiny/Fennec-Pharmaceuticals-Inc-.png"/></p>
<pre><code> 如需更多信息：Anthony J. Buffalano III
Southpoint Capital Advisors LP
1114 Avenue of the Americas, 22 楼
 纽约，NY 10036
 电话：（212）692-6356
</code></pre>

FENC

<p>Southpoint Capital Advisors LP 宣布以每股 7.50 美元出售 1,000,000 股 Fennec Pharmaceuticals Inc. 的普通股，持股比例降至 8%。此次出售是出于投资目的，Southpoint 可能会根据市场情况调整其持股</p>

<p>NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Southpoint Capital Advisors LP (“Southpoint”), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on December 24, 2025, pursuant to securities laws, it disposed of beneficial ownership of 1,000,000 common shares (a “Common Share”) of Fennec Pharmaceuticals Inc. (“Fennec”), representing approximately 2.93% of the outstanding Common Shares (calculated on a fully diluted basis).</p>
<div class="lb-trans"><p>纽约，2025 年 12 月 26 日（GLOBE NEWSWIRE）-- Southpoint Capital Advisors LP（“Southpoint”）作为其担任投资经理的某些 Southpoint 基金的代表，宣布于 2025 年 12 月 24 日，根据证券法，处置了 Fennec Pharmaceuticals Inc.（“Fennec”）的 1,000,000 股普通股（“普通股”）的实益拥有权，约占已发行普通股的 2.93%（按完全稀释基础计算）。</p>
</div><p>The Common Shares were sold at a price of USD$7.50 per Common Share.</p>
<div class="lb-trans"><p>普通股的出售价格为每股 7.50 美元。</p>
</div><p>Southpoint now exercises control or direction over an aggregate of 2.7 million Common Shares, and representing approximately 8% of the outstanding Common Shares (calculated on a fully diluted basis).</p>
<div class="lb-trans"><p>Southpoint 目前对总计 270 万股普通股行使控制或指挥权，约占已发行普通股的 8%（按完全稀释基础计算）。</p>
</div><p>Southpoint has disposed of the Common Shares for investment purposes. Depending on market and other conditions, Southpoint may change its beneficial ownership of, or control or direction over, Common Shares through market transactions, private agreements, treasury issuances, exercise of the Warrants or otherwise.</p>
<div class="lb-trans"><p>Southpoint 处置普通股是出于投资目的。根据市场和其他条件，Southpoint 可能会通过市场交易、私人协议、国库发行、行使认股权证或其他方式改变其对普通股的实益拥有权或控制或指挥权。</p>
</div><p>This press release has been issued in order to comply with applicable securities legislation.</p>
<div class="lb-trans"><p>本新闻稿的发布是为了遵守适用的证券立法。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56UXdOaU0zTXpNM01UWXpJekl3T0RrNE5URT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNzQwNiM3MzM3MTYzIzIwODk4NTE="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmQ5MWJkMjEtMDI0Zi00OGI2LWJlMmEtZDY4Y2I0MmZhMjE4LTExMDE0MjItMjAyNS0xMi0yNi1lbg==/tiny/Fennec-Pharmaceuticals-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MmQ5MWJkMjEtMDI0Zi00OGI2LWJlMmEtZDY4Y2I0MmZhMjE4LTExMDE0MjItMjAyNS0xMi0yNi1lbg==/tiny/Fennec-Pharmaceuticals-Inc-.png"/></p>
<pre><code>For further information: Anthony J. Buffalano IIISouthpoint Capital Advisors LP1114 Avenue of the Americas, 22nd FloorNew York, NY 10036Phone: (212) 692-6356
</code></pre>
<div class="lb-trans"><pre><code> 如需更多信息：Anthony J. Buffalano III
Southpoint Capital Advisors LP
1114 Avenue of the Americas, 22 楼
 纽约，NY 10036
 电话：（212）692-6356
</code></pre>
</div>

Southpoint 在 Fennec Pharmaceuticals Inc.（TSX: FENC）的持股情况 | FENC 股票新闻